How Much Will Mounjaro Increase By — and What That Means for You

The biggest misconception: the list price is what you pay

When news broke about the September 2025 price increase, a common assumption was that Eli Lilly's list price is the price patients pay. It isn't. The Mounjaro list price is a wholesale reference point (what a pharmacy pays to source the medicine) and private providers then set their own retail price to cover clinical costs, pharmacy overheads, prescriber time, delivery and aftercare. So when you read that the 15mg pen's list price rose from roughly £122 to roughly £330, that describes the supply-side shift, not a patient invoice.

What this means in practice is that reported private prices since the increase have ranged roughly £149 to £375 per month depending on the dose and the service. Those figures are widely cited and give a reasonable market sense, but they should be treated as indicative rather than fixed, providers have set their own positions differently. The dose matters too: lower doses carry lower list prices, so the jump at 2.5mg or 5mg looks quite different from the one at 15mg. If you want to understand exactly how the increase breaks down by dose, our breakdown of the 5mg price change covers the lower end of the schedule in detail.

The broader point is that Eli Lilly's September 2025 change was a genuine and significant uplift, as widely reported at the time. Anyone planning ongoing treatment should factor it into their thinking, but the list price alone doesn't tell you what you'll actually be charged.

What headline prices often leave out

A figure quoted online as a monthly price for Mounjaro is sometimes just the medicine cost. Underneath it there may be a separate consultation fee, a prescription charge, a delivery fee, and (less visibly) no real aftercare if something goes wrong after your pen arrives. Taken together, those additions can close much of the gap between a price that looks low and one that looks higher but is genuinely all-in.

It is also worth understanding what Mounjaro private pricing is supposed to include by design. A legitimate private prescription service has to cover a prescriber's time, identity and weight verification (a GPhC requirement), safe and trackable cold-chain logistics, and a mechanism for clinical review before each repeat. When a price looks unusually low, it is reasonable to ask which of those elements is missing.

There is a practical comparison worth making here. If you're considering treatment long-term (most people on Mounjaro stay on it for at least six to twelve months) a saving of £20 per pen adds up to something real. But so does the cost of a GP appointment to deal with a side effect that a prescriber could have caught in a routine review, or the stress of sourcing a pen when your usual supplier has run short with no clinical team to help you navigate it. The cost question is not just what you pay on day one.

Why our price is what it is, and what it covers

nume is not the cheapest option on the market. That is a deliberate choice, not an oversight. The price we charge for Mounjaro covers the free consultation, the prescription, the medicine itself, next-working-day DPD delivery in plain packaging, and 7-day-a-week aftercare from a clinical team that includes a GPhC-registered Independent Prescriber reviewing your case before every repeat order. There is no add-on fee at checkout. There is no subscription pulling money from your account when you haven't re-ordered.

For patients who ordered before the September 2025 list-price increase, the shift was visible and, for some, difficult. Our full guide to the Mounjaro price increase explains the background in detail, including what drove the change and what it means dose by dose. We also cover the broader cost trajectory for patients planning treatment over several months.

One thing worth knowing: if you order by 12pm on a working day and your consultation is clinically approved, your pen is dispatched the same day. For some people that's the detail that matters most, not just what they're paying, but that it actually arrives before the school run is done and the week has moved on without them.

Current treatment pricing is shown clearly on our weight-loss treatments page. We don't print per-pen figures in articles because prices can shift; the treatment page is always up to date.

For a prescription medicine, price is the wrong first question

Mounjaro is a Prescription Only Medicine. The MHRA has issued clear public guidance warning about counterfeit and illegally traded weight-loss pens, fake tirzepatide pens have been seized in the UK, including from an unlicensed manufacturing site discovered in Northampton in October 2025. The MHRA's Yellow Card scheme lets you report suspect sellers, and every legitimate pharmacy can be checked on the GPhC's pharmacy register, ours is registered under number 9012878.

A price that undercuts the market significantly is worth scrutinising, not celebrating. Sellers offering Mounjaro without a clinical assessment, through social media, or at prices well below those of registered pharmacies are red flags, not bargains. The cost of accessing a genuine, clinically supervised supply through a verified pharmacy is, frankly, the price of doing this safely.

How much will Mounjaro increase by in future? No further changes have been confirmed. What is confirmed is that understanding the current UK pricing landscape is the sensible starting point before committing to treatment, and if you experience side effects such as changes in bowel habits, our guidance on managing constipation on Mounjaro can help you work through what to expect and what to do. If you'd like to discuss your options, a free consultation with our prescribers is the place to start, no commitment, no charge to find out where you stand.